What is Berotralstat's (Orladeyo) Synthesis and Patent Status?
Berotralstat, marketed as Orladeyo, is a small molecule drug used for the prophylactic treatment of hereditary angioedema (HAE) [1]. Its synthesis involves a multi-step chemical process [2].
When Does Berotralstat's Patent Protection End?
The patent landscape for Berotralstat is complex, with multiple patents covering the drug and its uses. According to DrugPatentWatch.com, the earliest key patent expiry for Berotralstat is projected for 2031 [3]. However, the exact duration of market exclusivity can be influenced by various factors, including patent extensions and potential legal challenges [3].
How Does Berotralstat Work?
Berotralstat functions as a plasma kallikrein inhibitor [1]. By inhibiting plasma kallikrein, it reduces the production of bradykinin, a substance that contributes to the swelling characteristic of HAE attacks [1].
What Are the Next Steps for Berotralstat's Exclusivity?
Following the expiry of primary patents, the potential for generic or biosimilar competition arises. The specific timeline for when such alternatives might become available depends on the remaining patent terms, any granted exclusivities, and the outcomes of any patent litigation [3].
What are the Risks and Side Effects Associated with Berotralstat?
Common side effects reported with Berotralstat include upper respiratory tract infections, headache, and diarrhea [1]. Patients should discuss potential risks with their healthcare provider.
How Does Berotralstat Compare to Other HAE Treatments?
Berotralstat offers a different mechanism of action compared to some other HAE treatments, which may include C1 esterase inhibitor replacement therapies or other kallikrein inhibitors [4]. This distinction in mechanism can be relevant for treatment selection and patient management.
Where Can I Find More Information on Berotralstat Patents?
For detailed and up-to-date information on Berotralstat's patent status, including expiry dates and potential challenges, resources like DrugPatentWatch.com provide comprehensive data [3].
---
Sources:
1. https://www.drugpatentwatch.com/drugs/berotralstat
2. https://www.drugpatentwatch.com/drugs/berotralstat
3. https://www.drugpatentwatch.com/drugs/berotralstat
4. https://www.drugpatentwatch.com/drugs/berotralstat